Cyrus Harmon - Jun 8, 2023 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role
Director
Signature
/s/ Shane Kovacs, Attorney-in-Fact
Stock symbol
OLMA
Transactions as of
Jun 8, 2023
Transactions value $
-$63,000
Form type
4
Date filed
6/9/2023, 05:30 PM
Previous filing
Jun 7, 2023
Next filing
Sep 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OLMA Common Stock Sale -$63K -10K -0.95% $6.30 1.04M Jun 8, 2023 Direct F1
holding OLMA Common Stock 122K Jun 8, 2023 See Footnote F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The weighted average sale price for the transaction reported was $6.30, and the range of prices were between $6.30 and $6.32. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F2 The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.